>>Signaling Pathways>> GPCR/G protein>> Endothelin Receptor>>Sulfisoxazole

Sulfisoxazole (Synonyms: NSC 13120, NSC 33807, NSC 38588, NSC 683536, Sulfafurazole)

Catalog No.GC12231

설피속사졸(Sulfafurazole)은 엔도텔린 수용체 A 및 엔도텔린 수용체 B에 대해 IC50 값이 각각 0.60μM 및 22μM인 엔도텔린 수용체 길항제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

Sulfisoxazole Chemical Structure

Cas No.: 127-69-5

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$38.00
재고 있음
50mg
US$53.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Sulfisoxazole, an endothelin receptor antagonist, is a sulfonamide antibacterial with an oxazole substituent.Target: Antibacterial; Endothelin ReceptorThe sulfanilamide antibacterial agent sulfisoxazole was found to be a good endothelin receptor antagonist (IC50's of 0.60 microM and 22 microM for the ETA and ETB receptors, respectively) [1]. Sulfisoxazole is used to treat or prevent infections in many different parts of the body. It belongs to the group of medicines known as sulfonamide antibiotics. It works by preventing the growth of bacteria [2].

References:
[1]. Chan, M.F., et al., Identification of a new class of ETA selective endothelin antagonists by pharmacophore directed screening. Biochem Biophys Res Commun, 1994. 201(1): p. 228-34.
[2]. http://www.mayoclinic.org/drugs-supplements/sulfisoxazole-oral-route/description/drg-20072998

리뷰

Review for Sulfisoxazole

Average Rating: 5 ★★★★★ (Based on Reviews and 15 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Sulfisoxazole

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.